This work demonstrates prevention of lethality and other severe adverse consequences of therapeutic or unanticipated radiation injury such as pneumonitis, fibrosis, dermatitis, and esophagitis, by short-term treatment with innate immune TRAIL pathway agonists. This evidence concerns the gene TNFSF10 and dermatitis.